Nova Mentis Life Science Corp. (HN3Q.F)
| Previous Close | 0.0050 |
| Open | 0.0050 |
| Bid | 0.0050 x N/A |
| Ask | 0.0240 x N/A |
| Day's Range | 0.0050 - 0.0050 |
| 52 Week Range | 0.0005 - 0.0645 |
| Volume | |
| Avg. Volume | 555 |
| Market Cap | 1.507M |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings Date | May 30, 2024 - Jun 03, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Nova Mentis Announces Change of Directors
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") announces the appointment of Steve Loutskou to the Company's Board of Directors, effective February 23, 2024.Mr. Loutskou, a seasoned serial entrepreneur, boasts a career spanning over 20 years, marked by numerous success stories. From the initiation of early-stage start-ups to steering them through mature commercialization phases, he
- Newsfile
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased the Canadian government has established a new Implementation Advisory Group (IAG) for drugs for rare diseases, as part of its National Strategy to help facilitate informatio
- Newsfile
Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome
Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to provide an update on its Phase IIA clinical trial testing psilocybin for the treatment of fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder (
